Selected article for: "additional file and study group"
Author: Leaker, Brian R.; Singh, Dave; Lindgren, Sam; Almqvist, Gun; Eriksson, Leif; Young, Barbara; O’Connor, Brian
Title: Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study
  • Document date: 2019_12_19
    • ID: 15e043uf_29
    Snippet: A total of 51 patients were randomised and 43 patients (84%) completed the study, 22 in the AZD8848 group and 21 in the placebo group (Additional file 1: Figure S1 ). The baseline and demographic characteristics of the patients were similar between those randomised to AZD8848 and placebo groups. Although the sputum eosinophil levels were similar between the two groups, the AZD8848 group had a slightly lower baseline eosinophil count (Table 1) . .....
    Document: A total of 51 patients were randomised and 43 patients (84%) completed the study, 22 in the AZD8848 group and 21 in the placebo group (Additional file 1: Figure S1 ). The baseline and demographic characteristics of the patients were similar between those randomised to AZD8848 and placebo groups. Although the sputum eosinophil levels were similar between the two groups, the AZD8848 group had a slightly lower baseline eosinophil count (Table 1) . A total of 8 patients discontinued from the study prematurely mainly due to adverse events ( Table 2 ). The efficacy analysis set consisted of the 45 patients who were allocated treatment and had LAR data available.

    Search related documents:
    Co phrase search for related documents
    • additional file and analysis set: 1, 2, 3, 4
    • additional file and placebo group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
    • additional file and study discontinue: 1
    • adverse event and analysis set: 1, 2, 3
    • adverse event and demographic baseline: 1
    • adverse event and placebo group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • analysis set and efficacy analysis set: 1, 2
    • analysis set and placebo group: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • demographic baseline and placebo group: 1, 2, 3
    • eosinophil count and placebo group: 1, 2
    • eosinophil count and sputum eosinophil level: 1
    • eosinophil level and sputum eosinophil level: 1